Published on 2 May 2024 on Investor's Business Daily
Regeneron Reverses On Better-Than-Feared Eylea Sales As Patent Expiration Looms
Overall, revenue ticked down 1% to $3.15 billion, missing forecasts for $3.23 billion, according to...
NASDAQ.SNY price evolution
Want to become a better investor?
Start tracking your investments with Statfolio
Sign up for free